Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea.

In vivo (Athens, Greece) - 1 Jan 2000

Sogawa Rintaro, Nakashima Chiho, Nakamura Tomomi, Takeuchi Koji, Kimura Sakiko, Komiya Kazutoshi, Narisawa Yutaka, Kimura Shinya, Sueoka-Aragane Naoko

Abstract excerpt

BACKGROUND/AIM: Afatinib, a 2nd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used in treatment of non-small cell lung cancer (NSCLC), causes diarrhoea in over 90% of patients. The association of genetic background with diarrhoea is poorly understood. PATIENTS AND METHODS: We evaluated the roles of four single nucleotide polymorphisms (SNPs) in ATP binding cassette subfamily B...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to Diarrhea

Share to Incidence

Share to Neoplasm Proteins

Share to Odds Ratio

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32354939
DOI: 10.21873/invivo.11922
PMCID: PMC7279839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea.PMID 32354939Read ↗

Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.Semantic proximity Read ↗

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.Semantic proximity Read ↗

Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.Semantic proximity Read ↗

Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.Semantic proximity Read ↗

Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.Semantic proximity Read ↗

Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.Semantic proximity Read ↗

Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.Semantic proximity Read ↗

A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor.Semantic proximity Read ↗

The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid Tumors.Semantic proximity Read ↗

Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients.Semantic proximity Read ↗

Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients With EGFR-mutated Non-small Cell Lung Cancer Treated With Gefitinib: A Comprehensive Meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.